常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.39/0.67
|
|
企業價值
124.06M
|
| 資產負債 |
|
每股賬面淨值
0.39
|
| 現金流量 |
|
現金流量率
0.00
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2025/11/07 13:27 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in itsPhase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. |

1.41 
